About the journal
Drugs of the Future is a journal published by Thomson Reuters in Spain. It is listed in PUBMED according to the sources read. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Thomson Reuters
- ISSN
- 2013-0368 · 0377-8282
- Country
- Spain
- Access
- Not open access / not declared
Index listings
- PUBMED · 2009-04-01
- Indexing
- PUBMED
- APC
- —
- Declared review time (DOAJ)
- —
- Activity (OpenAlex)
- Active — latest works 2023
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Works in OpenAlex
6524
Last recorded publication year
2023
h-index
49
i10-index
540
From OpenAlex open data (CC0).
Editorial & policy4
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- Portico
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 0%
- ORCID iDs in current deposits
- 0%
Identity & continuity1
- Source type
- journal
Classification(no data)
No data available to the platform for this group
No platform data for: Classification — absence is not a judgment about the journal.
Subject areas
- Cancer Treatment and Pharmacology
- Cancer Treatment and Pharmacology
- Drug-Induced Ocular Toxicity
- Drug-Induced Ocular Toxicity
- Drug-Induced Adverse Reactions
- Drug-Induced Adverse Reactions
- Chronic Lymphocytic Leukemia Research
- Chronic Lymphocytic Leukemia Research
Show all subjects (50)
- Advanced Breast Cancer Therapies
- Advanced Breast Cancer Therapies
- Blood disorders and treatments
- Blood disorders and treatments
- Pharmacological Effects and Toxicity Studies
- Pharmacological Effects and Toxicity Studies
- Chemotherapy-related skin toxicity
- Chemotherapy-related skin toxicity
- Poisoning and overdose treatments
- Poisoning and overdose treatments
- Antibiotics Pharmacokinetics and Efficacy
- Antibiotics Pharmacokinetics and Efficacy
- Chronic Myeloid Leukemia Treatments
- Chronic Myeloid Leukemia Treatments
- Metabolism and Genetic Disorders
- Metabolism and Genetic Disorders
- Multiple Myeloma Research and Treatments
- Multiple Myeloma Research and Treatments
- Diverse Scientific and Economic Studies
- Diverse Scientific and Economic Studies
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- Hematological disorders and diagnostics
- Hematological disorders and diagnostics
- Cancer Immunotherapy and Biomarkers
- Cancer Immunotherapy and Biomarkers
- Urticaria and Related Conditions
- Urticaria and Related Conditions
- Melanoma and MAPK Pathways
- Melanoma and MAPK Pathways
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Epilepsy research and treatment
- Cancer therapeutics and mechanisms
- Cancer therapeutics and mechanisms
- Epilepsy research and treatment
- Pharmacology and Obesity Treatment
- Pharmacology and Obesity Treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- Monoclonal and Polyclonal Antibodies Research
- Monoclonal and Polyclonal Antibodies Research
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ